pathway. Yet, the underlying mechanisms are incompletely understood, and the pharmacological safety of the potential toxic and hazardous NO 3 Ϫ and NO 2 Ϫ is fragmentary, especially in consideration of the need for chronic use at quite high doses. As an example, right ventricular systolic pressure reduction in mice and blood pressure falls in humans were observed at NO 3 Ϫ doses being Ϸ3 orders of magnitude higher than those of traditional NO-releasing drugs. 1 Several heme enzymes hold the potential to convert NO 3 Ϫ or NO 2 Ϫ to NO under specific conditions, such as hypoxia or anoxia. Proposed enzymes include xanthine oxidoreductase and even NO synthase, as well as many other cytosolic and mitochondrial nitrite reductases. These enzymes are multifunctional, they are very poor NO 3 Ϫ and NO 2 Ϫ converters to NO, 1,2 and their enzymatic activity can be influenced by numerous NO-derived substances such as nitro-oleic acid (IC 50 , 0.6 mol/L toward xanthine oxidoreductase) 3 and even nitrite (IC 50 , 9 mol/L toward erythrocytic catalase). The conditions under which xanthine oxidoreductase, NO synthase, nitrate reductases, and nitrite reductases are found to produce NO from NO 3 Ϫ and NO 2 Ϫ are atypical to their inherent activity. In vitro testing NO 3 Ϫ /NO 2 Ϫ 3NO activity of such enzymes by using regular inhibitors, that is, inhibitors known to inhibit enzyme activity under normal conditions, such as N G -nitro-L-arginine methyl ester or N G -monomethyl-L-arginine, for NO synthase and allopurinol for xanthine oxidoreductase activity, under irregular conditions for pH and oxygen, may not be the best way to elucidate underlying mechanisms. 4 After several decades of vacuity, inorganic nitrite and nitrate are again in the focus of interdisciplinary research. This is because of their newly discovered potential to serve as readily available storage and transport forms of NO-related bioactivity. However, NO 3 Ϫ and NO 2 Ϫ are known for long time to bear harmful potential to health. Unequivocal delineation of the mechanisms leading to NO formation from NO 3 Ϫ and NO 2 Ϫ and re-evaluation of their safety are indispensable and emerging tasks, even in hardly healable diseases such as pulmonary hypertension.
To the Editor:
I read with great interest the recent article by Baliga et al 1 reporting that inorganic nitrite (NO 2 Ϫ ) or inorganic nitrate (NO 3 Ϫ ), given in drinking water, ameliorated pulmonary hypertension in mice. This work and previous studies by this and other groups indicate that NO 2 Ϫ and NO 3 Ϫ may exert vasodilatory effects in vivo and are, therefore, of particular pharmacological interest. 2 It is generally believed that the vasodilatory effects of NO 2 Ϫ and NO 3 Ϫ are finally exerted by nitric oxide (NO) and cGMP, that is, by the NO 3 Ϫ 3NO 2 Ϫ 3NO3cGMP pathway. Yet, the underlying mechanisms are incompletely understood, and the pharmacological safety of the potential toxic and hazardous NO 3 Ϫ and NO 2 Ϫ is fragmentary, especially in consideration of the need for chronic use at quite high doses. As an example, right ventricular systolic pressure reduction in mice and blood pressure falls in humans were observed at NO 3 Ϫ doses being Ϸ3 orders of magnitude higher than those of traditional NO-releasing drugs. 1 Several heme enzymes hold the potential to convert NO 3 Ϫ or NO 2 Ϫ to NO under specific conditions, such as hypoxia or anoxia. Proposed enzymes include xanthine oxidoreductase and even NO synthase, as well as many other cytosolic and mitochondrial nitrite reductases. These enzymes are multifunctional, they are very poor NO 3 Ϫ and NO 2 Ϫ converters to NO, 1,2 and their enzymatic activity can be influenced by numerous NO-derived substances such as nitro-oleic acid (IC 50 , 0.6 mol/L toward xanthine oxidoreductase) 3 and even nitrite (IC 50 , 9 mol/L toward erythrocytic catalase). The conditions under which xanthine oxidoreductase, NO synthase, nitrate reductases, and nitrite reductases are found to produce NO from NO 3 Ϫ and NO 2 Ϫ are atypical to their inherent activity. In vitro testing NO 3 Ϫ /NO 2 Ϫ 3NO activity of such enzymes by using regular inhibitors, that is, inhibitors known to inhibit enzyme activity under normal conditions, such as N G -nitro-L-arginine methyl ester or N G -monomethyl-L-arginine, for NO synthase and allopurinol for xanthine oxidoreductase activity, under irregular conditions for pH and oxygen, may not be the best way to elucidate underlying mechanisms. 4 After several decades of vacuity, inorganic nitrite and nitrate are again in the focus of interdisciplinary research. This is because of their newly discovered potential to serve as readily available storage and transport forms of NO-related bioactivity. However, NO 3 Ϫ and NO 2 Ϫ are known for long time to bear harmful potential to health. Unequivocal delineation of the mechanisms leading to NO formation from NO 3 Ϫ and NO 2 Ϫ and re-evaluation of their safety are indispensable and emerging tasks, even in hardly healable diseases such as pulmonary hypertension.
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